DGIdb - AMINOGLUTETHIMIDE Drug Record

AMINOGLUTETHIMIDE chembl:CHEMBL488 ApprovedAntineoplastic

Alternate Names:

AMINOGLUTETHIMIDE
ORIMETEN
CYTADREN
P-AMINOGLUTETHIMIDE
AMINOGLUTETIMIDE
ORI038
AMINOGLUTETHIMIDUM
ALPHA-(P-AMINOPHENYL)-ALPHA-ETHYLGLUTARIMIDE
AMINOGLUTETHIMID
AMINOGLUTETIMIDA
DL-AMINOGLUTETHIMIDE
Α-(P-AMINOPHENYL)-Α-ETHYLGLUTARIMIDE
2-(P-AMINOPHENYL)-2-ETHYLGLUTARIMIDE
3-ETHYL-3-(P-AMINOPHENYL)-2,6-DIOXOPIPERIDINE
CYTADREN®
AMINOGLUTÉTHIMIDE
drugbank:00357
pubchem.compound:2145
rxcui:677
chemidplus:125-84-8
chembl:CHEMBL488

Drug Info:

Year of Approval	1980
Drug Class	antineoplastic agents
FDA Approval	1980
Drug Class	small molecule
Drug Indications	Antineoplastic agents

(3 More Sources)

Publications:

Rahman et al., 2008, CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma., Drug Metab. Dispos.
Siraki et al., 2007, Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis., Chem. Res. Toxicol.
Shirakawa et al., 2006, Aminoglutethimide prevents excitotoxic and ischemic injuries in cortical neurons., Br. J. Pharmacol.
Greco et al., HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines., J Drug Target
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Martínez-Campa et al., 2005, Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells., Breast Cancer Res. Treat.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Block et al., 1992, Aminoglutethimide in malignant melanoma. A phase II study., Am. J. Clin. Oncol.
Slominski et al., 2006, An alternative pathway of vitamin D metabolism. Cytochrome P450scc (CYP11A1)-mediated conversion to 20-hydroxyvitamin D2 and 17,20-dihydroxyvitamin D2., FEBS J.
Oka et al., 2000, Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+ T cells in a murine model implanted with B16 melanoma., Cell. Immunol.
Johnson et al., 1984, Effects of aminoglutethimide on luteinizing hormone and steroid secretion, and ovulation in the hen, Gallus domesticus., Endocrinology
Brown et al., Assessment of thyrotoxicity using in vitro cell culture systems., Food Chem. Toxicol.
Bonneterre et al., 1987, Variations in lipoproteins during aminoglutethimide therapy., Breast Cancer Res. Treat.
May et al., 2015, TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer., Endocr. Relat. Cancer

AMINOGLUTETHIMIDE CYP11A1

Interaction Score: 22.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cytochrome P450 11A1 inhibitor

Direct Interaction yes

PMIDs:
16817851 11752352 11161433

Sources:
ChemblInteractions TTD
AMINOGLUTETHIMIDE TFF3

Interaction Score: 8.83

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25900183

Sources:
CIViC
AMINOGLUTETHIMIDE CYP19A1

Interaction Score: 3.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

Direct Interaction yes

Trial Name -

PMIDs:
17602675 16474421 16332571 11752352 16244789 17016423 17139284 1590282

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND TTD
AMINOGLUTETHIMIDE GNRH1

Interaction Score: 1.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6373241

Sources:
NCI
AMINOGLUTETHIMIDE GGT1

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3427227

Sources:
NCI
AMINOGLUTETHIMIDE TG

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3781413

Sources:
NCI
AMINOGLUTETHIMIDE CYP1B1

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18256205

Sources:
NCI

TEND: AMINOGLUTETHIMIDE
- Version: 01-August-2011
Alternate Names:

AMINOGLUTETHIMIDE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1980

Publications:
TdgClinicalTrial: AMINOGLUTETHIMIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antineoplastic agents

Drug Class small molecule

FDA Approval 1980

Publications:

NCI: AMINOGLUTETHIMIDE

Version: 14-September-2017

Alternate Names:

C233 NCI drug code

Drug Info:

Publications:

Rahman et al., 2008, CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma., Drug Metab. Dispos.

Block et al., 1992, Aminoglutethimide in malignant melanoma. A phase II study., Am. J. Clin. Oncol.

Bonneterre et al., 1987, Variations in lipoproteins during aminoglutethimide therapy., Breast Cancer Res. Treat.

CIViC: AMINOGLUTETHIMIDE
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

May et al., 2015, TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer., Endocr. Relat. Cancer
TTD: Aminoglutethimide
- Version: 2020.06.01
Alternate Names:

D0M6DO TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL488
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL488
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Cytochrome P450 11A1 inhibitor
Direct Interaction	yes

Mechanism of Interaction	Cytochrome P450 19A1 inhibitor
Direct Interaction	yes
Trial Name	-

AMINOGLUTETHIMIDE Drug Record

AMINOGLUTETHIMIDE chembl:CHEMBL488 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

AMINOGLUTETHIMIDE CYP11A1

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cytochrome P450 11A1 inhibitor Direct Interaction yes

PMIDs: 16817851 11752352 11161433

Sources: ChemblInteractions TTD

AMINOGLUTETHIMIDE TFF3

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25900183

Sources: CIViC

AMINOGLUTETHIMIDE CYP19A1

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cytochrome P450 19A1 inhibitor Direct Interaction yes Trial Name -

PMIDs: 17602675 16474421 16332571 11752352 16244789 17016423 17139284 1590282

Sources: TdgClinicalTrial ChemblInteractions NCI TEND TTD

AMINOGLUTETHIMIDE GNRH1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6373241

Sources: NCI

AMINOGLUTETHIMIDE GGT1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 3427227

Sources: NCI

AMINOGLUTETHIMIDE TG

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 3781413

Sources: NCI

AMINOGLUTETHIMIDE CYP1B1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18256205

Sources: NCI

TEND: AMINOGLUTETHIMIDE

Alternate Names: AMINOGLUTETHIMIDE Primary Drug Name

Drug Info: Drug Class antineoplastic agents Year of Approval 1980

Publications:

TdgClinicalTrial: AMINOGLUTETHIMIDE

Alternate Names:

Drug Info: Drug Indications Antineoplastic agents Drug Class small molecule FDA Approval 1980

Publications:

NCI: AMINOGLUTETHIMIDE

Alternate Names: C233 NCI drug code

Drug Info:

CIViC: AMINOGLUTETHIMIDE

Alternate Names:

Drug Info:

Publications: May et al., 2015, TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer., Endocr. Relat. Cancer

TTD: Aminoglutethimide

Alternate Names: D0M6DO TTD Drug ID

Drug Info:

Publications:

ChemblInteractions: CHEMBL488

Alternate Names:

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL488

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cytochrome P450 11A1 inhibitor

Direct Interaction yes

PMIDs:
16817851 11752352 11161433

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
25900183

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

Direct Interaction yes

Trial Name -

PMIDs:
17602675 16474421 16332571 11752352 16244789 17016423 17139284 1590282

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
6373241

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
3427227

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
3781413

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18256205

Sources:
NCI

Alternate Names:

AMINOGLUTETHIMIDE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1980

Drug Info:

Drug Indications Antineoplastic agents

Drug Class small molecule

FDA Approval 1980

Alternate Names:

C233 NCI drug code

Publications:

May et al., 2015, TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer., Endocr. Relat. Cancer

Alternate Names:

D0M6DO TTD Drug ID